Evidence map›Paper›PMID 32673206›Full record

ArticleDiagnostic and interventional radiology (Ankara, Turkey)2020

Liver-directed treatments of liver-dominant metastatic leiomyosarcoma.

Hailey Krzyston, Brian Morse, Danielle Deperalta, Anupam Rishi, Roger Kayaleh, Ghassan El-Haddad, Johnna Smith, Mihaela Druta, Bela Kis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic and interventional radiology (Ankara, Turkey), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hailey KrzystonDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA;University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.
Brian MorseDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
Danielle DeperaltaDepartment of Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Anupam RishiDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Roger KayalehDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA;University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.
Ghassan El-HaddadDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
Johnna SmithDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
Mihaela DrutaDepartment of Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Bela KisDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida, USA.
Moffitt Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to determine the safety and efficacy of liver-directed therapies in patients with unresectable metastatic leiomyosarcoma to the liver. Liver-directed therapies included in this study were transarterial chemoembolization with doxorubicin eluting beads (DEB-TACE), yttrium-90 (Y90) radioembolization, and percutaneous microwave ablation.

methodsThis is a single institution retrospective study of unresectable metastatic leiomyosarcoma to the liver treated with DEB-TACE, radioembolization, or microwave ablation. DEB-TACE was performed using 70-150 or 100-300 µ doxorubicin-loaded drug-eluting LC beads. Radioembolization was performed using Y90 glass microspheres. Electronic medical records were retrospectively reviewed to evaluate clinical and biochemical toxicities, tumor response on imaging, overall survival (OS), and liver progression-free survival (PFS).

resultsA total of 24 patients with metastatic leiomyosarcoma to the liver who underwent liver-directed treatment were identified (8 males, 16 females; average age, 62.8±11.4 years). Of these patients, 13 underwent DEB-TACE, 6 underwent Y90, and 5 underwent ablation. Three patients received a combination of treatments: one received Y90 followed by DEB-TACE, one received ablation followed by DEB-TACE, and one received ablation followed by Y90. Of the 24 patients, 19 received prior chemotherapy. At 3-month follow-up, grade 1 or 2 lab toxicities were found in 20 patients; 3 patients had grade 3 toxicities. A grade 3 clinical toxicity was reported in one patient. MELD score was 7.5±1.89 at baseline and 8.8±4.2 at 3 months. Median OS was 59 months (95% CI, 39.8-78.2) from diagnosis, 27 months (95% CI, 22.9-31.0) from development of liver metastasis, and 9 months (95% CI, 0-21.4) from first liver-directed treatment. Median liver PFS was 9 months (95% CI, 1.4-16.6).

conclusionTreatment with liver-directed therapies for patients with unresectable metastatic leiomyosarcoma to the liver is safe and can improve overall survival, with OS after liver-directed therapy being similar to patients who underwent surgical resection.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLeiomyosarcomaLiver NeoplasmsPharmaceutical PreparationsDoxorubicinFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeDoxorubicinPharmaceutical Preparations

Identifiers

PMID32673206
PMCPMC7490031
OpenAlexW3040722082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.